Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07227168 · ClinicalTrials.gov registry record · Phase 1

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

A Phase 1 study of Colorectal Cancer and Endometrial Cancer, sponsored by Sutro Biopharma.

Recruiting
Registry status
Phase 1
Development phase
200
Enrollment target
6
Study locations

NCT07227168 is a Phase 1 study of Colorectal Cancer and Endometrial Cancer that is actively recruiting participants, run by Sutro Biopharma. The registered enrollment target is 200 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (87% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07227168, a Phase 1 study of Colorectal Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Sutro Biopharma.

RECRUITING
Registry status
Phase 1
Development phase
200 participants
Enrollment target
6
Study locations

Study Summary

This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a cohort expansion in 1 or more types of cancer to further evaluate a STRO-004 monotherapy dose, determine the best dose for use in later phases, and examine anti-tumor activity. * Part 1C is a dose escalation of STRO-004 combined with pembrolizumab to determine tolerability and preliminary anti-tumor activity of both drugs used together.

Conditions Studied

Colorectal Cancer Endometrial Cancer Gastric Cancer Cervical Cancer Esophageal Cancer Non-small Cell Lung Cancer (NSCLC) Urothelial Cancer Pancreatic Ductal Adenocarcinoma (PDAC) Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions

  • DRUG Pembrolizumab
  • DRUG STRO-004

Study Locations (6)

Texas

  • NEXT Austin - Austin
  • NEXT San Antonio - San Antonio

Colorado

  • SCRI Denver - Denver

Florida

  • SCRI FCS Sarasota - Sarasota

Massachusetts

  • Mass General Cancer Center - Boston

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-11-07
Est. Completion 2028-04
Phase Phase 1

Sponsor

Sutro Biopharma

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07227168

The ClinicalTrials.gov registry entry for NCT07227168 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Sutro Biopharma, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT07227168 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT07227168 about?

NCT07227168 is a clinical study titled "A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer". This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh...

What is the current status of trial NCT07227168?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2025-11-07. Estimated completion is 2028-04.

What conditions does trial NCT07227168 study?

This clinical trial studies the following conditions: Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Cervical Cancer, Esophageal Cancer.

What interventions are being tested in trial NCT07227168?

The interventions under investigation include: Pembrolizumab (DRUG), STRO-004 (DRUG).

Who is sponsoring clinical trial NCT07227168?

This trial is sponsored by Sutro Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07227168 being conducted?

This trial has 6 study locations across Colorado, Florida, Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Endometrial Cancer

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.